<< InfoSite Home
Proven Efficacy in Severe Alzheimer's Disease
Read Patient ProfileImprove ability to perform daily activities
In severe patients, improvements in areas such as mobility, eating, fluid intake, and toilet use may help reduce care dependence.
NAMENDA significantly improves functional behavior16
Results of a randomized, multicenter, double-blind, parallel-group, placebo-controlled study (N=166) investigating the clinical benefits of NAMENDA in severe dementia (MMSE <10 points): AD or vascular dementia (49% and 51%, respectively) in nursing home patients. Results shown are from a treated-per-protocol population. Patients ranged from 60 to 80 years of age. Patients were randomized for treatment with NAMENDA (10 mg daily) or placebo for 12 weeks. At week 12, 151 patients (75 NAMENDA, 76 placebo) completed the study.16
- Patients treated with NAMENDA vs placebo (P<0.05) were significantly better able to: stand up, move, wash, take a shower/bath, dress, use the toilet, participate in group activities and hobbies/interests16
*D-Scale=Dementia Scale. Designed and validated to descriptively evaluate behavioral activities and functioning in demented geriatric patients by a nurse on a 6-point scale.
Sixteen functional variables, including those listed in the chart, comprise important criteria for characterizing independence. Communication Understanding and Communication Expression are considered components of one functional variable.16,24
Important Safety Information
NAMENDA® (memantine HCl) is indicated for the treatment of moderate to severe Alzheimer's disease. NAMENDA has been used by more than 2 million people worldwide.NAMENDA is contraindicated in patients with known hypersensitivity to memantine HCl or any excipients used in the formulation. The most common adverse events reported with NAMENDA vs placebo (≥5% and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, the dosage should be reduced.
See Full Prescribing Information